Allogeneic Gene-edited CD33-knockout Hematopoietic Stem and Progenitor Cells

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of human allogeneic hematopoietic stem and progenitor cells (HSPCs) that are ex-vivo gene-edited to remove the cluster of differentiation 33 (CD33) antigen, that can potentially be used to improve hematopoietic recovery after hematopoietic cell transplantation (HCT) and CD33-targeting therapy. Upon administration, allogeneic gene-edited CD33-knockout HSPCs increase and restore the number of HSPCs, which may prevent or decrease infection and other complications of HCT and chemotherapy-induced neutropenia (CIN). The removal of CD33 protects the agent from the cytotoxic effects of CD33-targeted agents administered after HCT.

**Synonyms:** - Allogeneic CD33KO-HSPC - Allogeneic Gene-edited CD33-depleted HSCs - Allogeneic Gene-edited CD33-knockout HSPCs